1912399-75-7

Usage

Uses

Used in Agriculture:
BT11 is used as a pest-resistant crop for protecting corn fields from the European corn borer. The presence of the Cry1Ab protein in BT11 provides a natural defense mechanism against these pests, reducing the need for chemical insecticides and contributing to more sustainable agricultural practices.
Used in Environmental Conservation:
By reducing the need for chemical insecticides, BT11 is used as an environmentally friendly alternative in farming. This helps in minimizing the environmental impact of agriculture, such as reducing soil and water contamination, and promoting biodiversity.
Used in Crop Yield Improvement:
The pest resistance provided by BT11 is used to enhance crop yields by reducing the damage caused by the European corn borer. This leads to healthier crops and potentially higher production, which can be beneficial for both farmers and the food supply chain.
Used in Regulatory Approvals:
BT11 has been approved for commercial use in various countries, including the United States and Canada, indicating its acceptance as a safe and effective solution for pest management in agriculture. This approval is based on extensive research and testing to ensure the safety of the crop for both the environment and human consumption.

Upstream product

• 110-85-0 piperazine 
• 144493-38-9 6-(1'H-benzimidazol-2'-yl)pyridine-2-carboxylic acid 

Relevant academic research and scientific papers

An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease

Lanthionine synthetase C-like 2 (LANCL2), a novel therapeutic target for inflammatory and autoimmune diseases and diabetes, exerts anti-inflammatory and insulin-sensitizing effects. This study reports the first LANCL2-based therapeutics for inflammatory bowel disease (IBD). Analogues of 1 (ABA) and 2 (NSC61610) were screened by molecular docking, then synthesized and analyzed for binding to LANCL2 by surface plasmon resonance. Piperazine-1,4-diylbis(6-benzo[d]imidazole-2-yl)pyridine-2-yl)methanone, 7, was identified as the lead LANCL2-binding compound for treating IBD. The oral treatment with 7 (8 mg/kg/d) in a mouse model of IBD resulted in lowering the disease activity index, decreasing colonic inflammatory lesions by 4-fold, and suppressing inflammatory markers (e.g., TNF-α, and interferon-γ) in the gut. Furthermore, studies in LANCL2-/- mice demonstrated that loss of LANCL2 abrogated beneficial actions of 7, suggesting high selectivity for the target. In conclusion, 7 merits continued development as a LANCL2-based, first-in-class orally active therapeutic for IBD.

LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.